MedTrace Logo

Immune Failure in Critical Therapy (INFECT) Study

NCT02186522 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 168

Last updated 2016-10-26

No results posted yet for this study

Summary

Patients admitted to intensive care units (ICU) are at high risk of developing secondary infections, and this is in part due to dysfunction or failure of their 'germ killing' functions (the immune system). Our group has recently identified three signatures of immune system failure which can be readily detected on a blood sample, and importantly, appear to predict the chances of developing secondary infection. Such a test would have major benefits for the management of patients in intensive care if it can be translated into a test usable in everyday clinical practice. This study aims to validate our original findings in a cohort of patients from multiple ICUs, using a test which will be suitable for everyday clinical practice, and thus take the next step towards developing a market-ready test.

Study hypothesis:

Measurement of neutrophil CD88, monocyte HLA-DR and percentage Tregs will accurately predict the risk of nosocomial infection.

Conditions

Sponsors & Collaborators

  • Technology Strategy Board, United Kingdom

    collaborator OTHER

  • Becton, Dickinson and Company

    collaborator INDUSTRY

  • University of Edinburgh

    lead OTHER

Principal Investigators

  • Andrew Conway Morris, MD · University of Cambridge

  • Tim S Walsh, MD · NHS Lothian/University of Edinburgh

  • John Simpson, MD · Newcastle University

  • Alistair Roy, MD · City Hospitals Sunderland NHS Foundation Trust

  • Alun Brown · Guy's and St Thomas' NHS Foundation Trust

  • Manu Shankar-Hari, MD · Guy's and St Thomas' NHS Foundation Trust

  • Anthony Bateman, MD · NHS Lothian (Western General Hospital)

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2016-01-31
Completion
2016-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02186522 on ClinicalTrials.gov